Patients with primary unresected locoregionally advanced HNSCC , in good clinical condition with unfavourable risk of recurrence , and no evidence of disease after chemoradiotherapy will be randomized 2:1 to oral once-daily afatinib ( 40 mg starting dose ) or placebo .